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Concurrent activation of RAS/ERK and PI3K/AKT pathways is implicated in prostate cancer progression. 
The negative regulators of these pathways, including sprouty2 (SPRY2), protein phosphatase 2A (PP2A), and 
phosphatase and tensin homolog (PTEN), are commonly inactivated in prostate cancer. The molecular basis 
of cooperation between these genetic alterations is unknown. Here, we show that SPRY2 deficiency alone trig-
gers activation of AKT and ERK, but this is insufficient to drive tumorigenesis. In addition to AKT and ERK 
activation, SPRY2 loss also activates a PP2A-dependent tumor suppressor checkpoint. Mechanistically, the 
PP2A-mediated growth arrest depends on GSK3β and is ultimately mediated by nuclear PTEN. In murine pros-
tate cancer models, Pten haploinsufficiency synergized with Spry2 deficiency to drive tumorigenesis, including 
metastasis. Together, these results show that loss of Pten cooperates with Spry2 deficiency by bypassing a novel 
tumor suppressor checkpoint. Furthermore, loss of SPRY2 expression correlates strongly with loss of PTEN 
and/or PP2A subunits in human prostate cancer. This underlines the cooperation between SPRY2 deficiency 
and PTEN or PP2A inactivation in promoting tumorigenesis. Overall, we propose SPRY2, PTEN, and PP2A 
status as an important determinant of prostate cancer progression. Characterization of this trio may facilitate 
patient stratification for targeted therapies and chemopreventive interventions.
Introduction
Prostate cancer (PC) is the most common malignancy among 
adult men in the developed world. Despite early diagnosis and 
treatment, many patients relapse and develop aggressive castrate-
resistant PC (CRPC). Recent studies have implicated the activa-
tion of both PI3K/AKT and RAS/ERK pathways by aberrant 
receptor tyrosine kinase (RTK) signaling in the development of 
aggressive CRPC (1). Failing to detect significant mutations or 
amplifications of RTKs, integrated genomic analyses have high-
lighted the involvement of PI3K/AKT and RAS/ERK pathways 
at a relatively high frequency (43%) in primary PC and almost 
universally in metastatic disease (2). Dual activation of PI3K and 
RAS pathways has been implicated in bypassing primary tumor-
suppressive responses such as growth arrest and senescence (3, 4). 
Interestingly, expression of phosphatase and tensin homolog 
(PTEN) and sprouty2 (SPRY2), key negative feedback regulators 
of the PI3K and RAS cascades, is decreased at higher frequencies 
than mutational activation of oncogenes such as PI3KCA, KRAS, 
and BRAF (2, 5). This strongly suggests cooperative interactions 
among these pathway-specific lesions in PC progression, and 
insight into how these alterations confer selective advantage to 
tumorigenesis will facilitate biology guided patient stratification 
and therapeutic design.
RTK-mediated activation of PI3K increases phosphatidylinosi-
tol 3,4,5 phosphate (PIP3) levels, leading to AKT activation (6). 
The lipid phosphatase PTEN acts as the central negative regula-
tor of the PI3K/AKT pathway by dephosphorylating PIP3. PTEN 
is a commonly mutated tumor suppressor in human cancer (7). 
Phosphorylated PTEN is unable to associate with the membrane 
due to conformational change and hence fails to inhibit PI3K 
signaling (8). In addition to its role at the cell membrane, PTEN 
can also act as a tumor suppressor in the nucleus by binding and 
stabilizing tumor protein p53 (TP53) to induce growth arrest and 
apoptosis (9, 10). Extensive in vivo studies show that Pten is a 
haploinsufficient tumor suppressor, and the extent of its inacti-
vation can determine PC progression (11). Pten heterozygous mice 
develop prostate intraepithelial neoplasia, whereas complete loss 
of functional Pten leads to tumor formation (12). In agreement 
with this, while mutations in the PTEN gene are rare, primary 
prostate tumors often show loss or alteration in one of the PTEN 
alleles. Complete inactivation of PTEN appears to be a late event 
in cancer progression (13). Recent studies have suggested that 
deregulated expression of PTEN interacting proteins and altered 
PTEN regulation by posttranslational modifications may also 
contribute to prostate carcinogenesis (14). It could be postulated 
that loss of PTEN activity may play an important role in tumor 
initiation, while further reduction in its expression can aid car-
cinogenesis. Hence it becomes important to study regulation of 
PTEN and how disruption of this is involved in tumorigenesis.
Sprouty proteins (SPRY1–4) are a family of well-conserved nega-
tive regulators of RTKs. Sprouty was originally identified in Dro-
sophila as an antagonist of FGF signaling (15). Overall, SPRY2 is a 
tumor suppressor, and its expression is repressed in breast, lung, 
and liver cancers (16). However, in certain cancers, such as colonic 
adenocarcinoma, SPRY2 can also function as an oncogene (17). 
Consistent with its tumor-suppressive role, SPRY2 overexpres-
sion suppressed proliferation, motility, and invasion in cultured 
tumor cells (18). SPRY2 is a well-established inhibitor of the RAS/
ERK signaling cascade, and it can act as a tumor suppressor in 
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lung cancer by inhibiting ERK activation (19). SPRY2 also binds 
to and interacts with other tumor suppressors such as protein 
phosphatase 2A (PP2A) (20). However, how SPRY2 influences 
the function of PP2A remains unclear. PP2A is a ubiquitously 
expressed multimeric serine/threonine phosphatase, accounting 
for a large fraction of the phosphatase activity in eukaryotic cells 
(21). Suppression of PP2A activity can transform multiple cell 
types by activating key pathways such as PI3K and RAS (22).
Figure 1
SPRY2 KD decreases cell proliferation despite activation of mitogenic signaling. (A) Whole cell lysates (WCL) of Nsi VC and SPRY2 KD DU145 
clones were analyzed by Western blot (WB). (B and C) WCLs of (B) MEFs and (C) prostatic tissue from mice as indicated were analyzed by 
Western blot (n = 3). (D and E) BrdU incorporation analysis on (D) DU145 and (E) MEFs with indicated genetic alterations (*P < 0.001, **P < 0.05; 
n = 3; analyzed by Mann-Whitney test). Data are presented as mean ± SEM. (F) Representative IHC images and quantification for Ki67 staining 
in prostates of indicated mice. Scale bars: 100 μm. Arrows indicate Ki67-positive nuclei. (*P < 0.01, **P < 0.001; number of mice analyzed = 5 
analyzed by Dunnett’s multiple comparison test). Box and whisker plots show median (lines within boxes), interquartile range (bounds of boxes), 
and upper and lower range (whiskers). All the Western blots were quantified using ImageJ, and the values represent relative immunoreactivity of 
each protein normalized to respective loading control.
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Genomic profiling of clinical PC showed SPRY2 inactivation in 
almost 18% of primary and over 70% of metastatic tumors, sup-
porting a probable tumor-suppressive role for SPRY2 in PC (2). 
We have previously reported that epigenetic silencing of SPRY2 
is a common event in prostate tumors (5). Edwin et al. showed 
that, in addition to the RAS/ERK pathway, SPRY2 can also reg-
ulate PI3K signaling by enhancing lipid phosphatase function 
of PTEN (23). Thus, SPRY2 can act as a tumor suppressor by 
inhibiting both RAS/ERK and PI3K/AKT signaling cascades. 
Understanding the molecular basis and functional consequence 
of tumor suppressors, especially when molecular and genomic 
analyses implicate 2 tumor suppressors, e.g., SPRY2 and PTEN 
Figure 2
SPRY2 loss induces PTEN-mediated G1 arrest. (A and B) Western blot and BrdU incorporation analysis on (A) PC3 and (B) LNCaP cells (*P < 0.001; 
n = 3, analyzed by Mann-Whitney test). (C and D) Representative orthotopic tumor images and the weights of prostate following injection with (C) 
DU145 and (D) LNCaP cells as indicated. (*P < 0.01, number of mice = 5, analyzed by Dunnett’s multiple comparison test). Scale bars: 0.5 cm. 
Box and whisker plots show median (lines within boxes), interquartile range (bounds of boxes), and upper and lower range (whiskers). (E) SPRY2 
KD DU145 were analyzed for cell-cycle profiles (top panel) after thymidine block release, and percentage of G1 cells are in bar chart (bottom 
panel; *P < 0.01; n = 3, analyzed by Mann-Whitney test). (F) SPRY2 KD DU145 transfected with PTEN siRNA were analyzed by Western blot 
and the G1 cells quantified. (*P < 0.01; n = 3, analyzed by Mann-Whitney test). (G) MEFs as indicated were quantified for cells in G1 (*P < 0.001; 
**P < 0.01; n = 3, analyzed by Mann-Whitney test). All Western blots were quantified using ImageJ, and the values represent relative immunore-
activity of each protein normalized to respective loading control. Data (A, B, F, and G) presented as mean ± SEM.
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within the same pathway, poses an important problem in can-
cer biology. Here, by profiling the tumor-suppressive roles of 
SPRY2 and PTEN in a coherent set of in vitro and in vivo sys-
tems, we showed that SPRY2 deficiency is sufficient to activate 
both PI3K/AKT and RAS/ERK cascades. However, despite such 
dual pathway activation, SPRY2-deficient cells exhibit growth 
arrest induced by nuclear PTEN, independent of its canonical 
lipid phosphatase activity. Mechanistically, our data revealed 
important interplay among established tumor suppressors 
PTEN, PP2A, GSK3B, and TP53 in restraining PC. Overall, we 
have identified the cooperative role of concomitantly inactivated 
components of PI3K and RAS pathways, namely SPRY2, PTEN, 
and PP2A, to drive PC progression.
Results
SPRY2 knockdown decreases cell proliferation despite activation of mito-
genic signaling. The effects of SPRY2 expression on activation of 
mitogenic signaling effectors such as AKT and ERK were inves-
tigated in DU145 PC cells with stable SPRY2 knockdown (KD). 
DU145 clones with stable SPRY2 KD (CL13 and CL61) showed 
increased PTEN phosphorylation and decreased membrane 
localization with an associated activation of PDK-1 and AKT 
when compared with nonsilencing (Nsi) vector control (VC) cells 
(Figure 1A and Supplemental Figure 1A; supplemental material 
available online with this article; doi:10.1172/JCI63672DS1). 
Stable overexpression of SPRY2 in DU145 cells enhanced mem-
brane localization of PTEN with a corresponding reduction in 
phosphorylation of PTEN, PDK-1, and AKT (Supplemental Fig-
ure 1, A and B). To confirm the role of PTEN phosphorylation 
in AKT activation, WT and phosphorylation-deficient PTEN 
mutants (PTENS380F and PTENT382/383A) were expressed in 
control and SPRY2-expressing (PTEN deficient) LNCaP cells. In 
the presence of WT PTEN, SPRY2-deficient LNCaP cells showed 
increased phosphorylated PTEN (p-PTEN) and p-AKT levels. 
However, p-AKT levels were significantly decreased in the pres-
ence of phosphorylation-deficient PTEN mutants in SPRY2-
deficient LNCaP cells (Supplemental Figure 1C). In the presence 
of WT PTEN, SPRY2 expression in LNCaP cells reduced p-PTEN 
and p-AKT levels. Thus, SPRY2 deficiency decreased PTEN activ-
ity to inhibit PI3K/AKT signaling. Furthermore, SPRY2 KD ele-
vated and SPRY2 overexpression decreased p-ERK1/2 levels in 
DU145 cells, underscoring the role of SPRY2 as a negative regu-
lator of RAS/ERK signaling (Figure 1A and Supplemental Fig-
ure 1B). Similarly, Spry2 heterozygous (Spry2+/–) mouse embry-
onic fibroblasts (MEFs) showed enhanced Pten, Akt, and Erk 
phosphorylation when compared with WT MEFs (Figure 1B). 
The increased phosphorylation of PTEN, Akt, and Erk was also 
observed in prostatic tissue from PB-Cre4: Spry2+/– mice when 
compared with WT (Figure 1C).
We next investigated the role of SPRY2 expression on cell pro-
liferation. When compared with the Nsi control, BrdU incorpo-
ration was significantly decreased in stable SPRY2 KD DU145 
clones (CL13 and CL61) (Figure 1D). These effects were also vali-
dated by knocking down SPRY2 transiently in DU145 and normal 
prostatic RWPE-1 cells (Supplemental Figure 1D). As expected, 
SPRY2 KD–induced growth arrest in DU145 cells was rescued 
by expressing WT SPRY2 (Supplemental Figure 1E). The Spry2+/– 
MEFs also showed decreased cell proliferation with concomitant 
upregulation of p21 when compared with WT MEFs, supporting 
the notion that SPRY2 loss induced growth arrest despite increased 
Akt and Erk activation (Figure 1, B and E). The prostatic tissue of 
PB-Cre4: Spry2+/– mice also showed increased p21 (Waf1/Cip1) 
levels and decreased Ki67 staining indicative of probable growth 
arrest despite increased activation of mitogenic signaling (Figure 1, 
C and F). Interestingly, PB-Cre4: Ptenfl/+Spry2+/– (dual Pten and Spry2 
heterozygous) prostates and MEFs showed elevated Ki67 and 
decreased p21 levels with associated increases in Akt and Erk acti-
vation when compared with PB-Cre4: Spry2+/– (Figure 1, B, C, E, and 
F). Overall, this suggests a potential growth-suppressive function of 
PTEN in SPRY2-deficient cells independent of its inhibitory effects 
on the PI3K/AKT pathway.
SPRY2 deficiency induces PTEN-mediated growth arrest. To inves-
tigate the tumor-suppressive functions of PTEN in SPRY2-defi-
cient cells, cell proliferation was assayed in PTEN-deficient PC-3 
cells with stable SPRY2 KD. When compared with Nsi controls, 
BrdU incorporation was significantly increased in stable SPRY2 
KD PC-3 clones (CL1 and CL10) (Figure 2A). This was also con-
firmed by knocking down SPRY2 transiently in PC-3 cells (Sup-
plemental Figure 2A). Furthermore, stable WT SPRY2 expres-
sion significantly decreased BrdU incorporation in SPRY2- and 
PTEN-deficient LNCaP cells (Figure 2B). We next investigated 
the impact of SPRY2 and PTEN status on prostate tumorigenesis 
using an orthotopic prostate tumor model. SPRY2 KD DU145 
(PTEN proficient) (CL61) cells and SPRY2-expressing LNCaP 
(PTEN deficient) cells along with the respective controls were 
injected into the dorsolateral prostate of nude mice. As expected, 
after 8 weeks, tumor incidence in mice with DU145 Nsi cells was 
100%, with significant increase in tumor burden, whereas tumor 
incidence in mice with SPRY2 KD cells was under 30% with no sig-
nificant increase in tumor burden (Figure 2C). In PTEN-deficient 
LNCaP cells, VC cells formed larger tumors when compared with 
corresponding SPRY2-expressing LNCaP cells (Figure 2D). The 
cell-cycle analyses showed that SPRY2 KD in DU145 cells resulted 
in slower G1 to S transit and accumulation of cells in G1 indicat-
ing pronounced G1 arrest (Figure 2E and Supplemental Figure 
2B). To confirm the role of PTEN in observed G1 arrest, PTEN 
was transiently knocked down in SPRY2 KD DU145 cells. PTEN 
KD released SPRY2 KD DU145 cells from G1 arrest and increased 
their proliferation (Figure 2F and Supplemental Figure 2C). This 
was further confirmed in SPRY2- and PTEN-deficient LNCaP 
cells where SPRY2 and PTEN expression induced G1 arrest only 
in SPRY2-deficient cells (VC) (Supplemental Figure 2D). Also, 
Figure 3
SPRY2 loss–induced G1 arrest is mediated by nuclear accumulation of 
PTEN. (A) Representative immunofluorescence (IF) images of indicated 
DU145 cells stained for PTEN (green), p21 (red), and DAPI (blue) (n = 3). 
Scale bars: 50 μm. (B and C) Representative immunofluorescence 
images of WT and Spry2+/– (B) MEFs and (C) prostate tissue stained 
for Pten (green). Red arrows indicate selected nuclei positive for Pten 
(n = 5). Scale bars: 100 μm. (D) Representative immunofluorescence 
images of indicated MEFs stained for Trp53 (green), p21 (red), and 
DAPI (blue). Scale bars: 100 μm. (E) Representative images and 
quantitation of DU145 orthotopic tumors stained for H&E, BrdU, and 
PTEN (*P < 0.01 **P < 0.001; n = 5, analyzed by Mann-Whitney test). 
Scale bars: 100 μm. Box and whisker plots show median (lines within 
boxes), interquartile range (bounds of boxes), and upper and lower 
range (whiskers). (F) SPRY2-LNCaP cells transfected with indicated 
plasmids were analyzed for cell-cycle profile after 24 hours (*P < 0.01; 
**P < 0.05 n = 3, analyzed by Mann-Whitney test). Data are presented 
as mean ± SEM.
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Figure 4
SPRY2 deficiency induces TP53-dependent G1 arrest via nuclear PTEN. (A) Western blot analysis of indicated DU145 cells transfected with 
PTEN siRNA. (B) Western blot analysis of PTEN IP from DU145. (C) Western blot analysis for LNCaP cells transfected with indicated plasmids. 
(D) DU145 cells transfected with TP53 siRNA were analyzed by Western blot and quantified for cells in G1. (*P < 0.01; n = 3, analyzed by Mann-
Whitney test). Data are presented as mean ± SEM. (E) Representative IHC images for Srpy2, Trp53, and p21 in prostates of mice as indicated 
(n = 4). Scale bars: 50 μm. All Western blots were quantified using ImageJ, and the values represent relative immunoreactivity of each protein 
normalized to respective loading control.
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Spry2+/– MEFs showed increased G1 arrest, which was significant-
ly reduced in Spry2 and Pten heterozygous (Ptenfl/+Spry2+/–) MEFs 
(Figure 2G). Overall, PTEN inhibited tumorigenesis in SPRY2-
deficient cells by inducing growth arrest.
Nuclear PTEN mediates SPRY2 deficiency–induced growth arrest. 
Since the SPRY2-deficient DU145 cells show decreased mem-
brane levels of PTEN, cellular distribution of PTEN was assayed. 
The SPRY2 KD DU145 cells showed increased nuclear PTEN 
staining with associated increases in nuclear p21 staining when 
compared with Nsi cells (Figure 3A). This was further confirmed 
by cell fractionation in which nuclear fractions showed elevated 
PTEN levels in SPRY2 KD cells and decreased PTEN levels in 
SPRY2-overexpressing cells (Supplemental Figure 3A). SPRY2-
mediated regulation of nuclear PTEN was also confirmed in 
other prostate cells (Supplemental Figure 3, B and C). Similarly, 
in SPRY2-deficient LNCaP cells, GFP-PTEN showed enhanced 
nuclear localization (Supplemental Figure 3D). Increased 
nuclear Pten staining was also observed in Spry2+/– MEFs and 
prostatic tissue when compared with WT (Figure 3, B and C, 
and Supplemental Figure 3E). The Spry2+/– MEFs also showed 
associated increase in nuclear transformation–related protein 
53 (Trp53) and p21 staining relative to WT MEFs, underscor-
ing the G1 arrest observed in these cells (Figure 3D, Supplemen-
tal Figure 3F, and Figure 2G). The smaller orthotopic tumors 
formed by SPRY2 KD DU145 cells showed lower BrdU labeling 
and enhanced nuclear PTEN staining when compared with Nsi 
tumors (Figure 3E). To confirm the relative impact of nuclear 
and cytoplasmic PTEN in inducing growth arrest, LNCaP cells 
were transfected with WT-PTEN tagged with either nuclear 
exclusion sequence (NES) or nuclear localizing sequence (NLS). 
Since SPRY2 influenced PTEN phosphatase function (23), phos-
phatase-dead PTEN-G129R mutant was also studied. As expect-
ed, WT-PTEN expression induced G1 arrest only in SPRY2-
deficient cells (Figure 3F). In LNCaP cells, irrespective of SPRY2 
expression, nuclear (NLS) PTEN (WT and G129R) induced G1 
arrest, indicating that nuclear PTEN was sufficient to induce G1 
arrest in a phosphatase-independent manner (Figure 3F). Irre-
spective of SPRY2 expression, cytosolic expression of WT PTEN 
enhanced sub-G1 population, indicating cell death, while the 
G1 population was relatively unaffected (Figure 3F). Thus, the 
observed growth arrest in SPRY2-deficient cells is mediated by 
nuclear PTEN.
Nuclear PTEN induces p53-dependent growth arrest. Since both 
SPRY2 KD cells and Spry2+/– MEFs showed increased p21 lev-
els and nuclear PTEN staining, the effects of PTEN on TP53-
mediated G1 arrest were investigated. Although DU145 cells 
express mutant TP53 alleles, the mutant TP53 retains its abil-
ity to induce p21-mediated growth arrest (24). Compared with 
Nsi, SPRY2 KD DU145 cells showed elevated levels of TP53 and 
p21, which were decreased by PTEN KD (Figure 4A). Similarly, 
Ptenfl/+Spry2+/– MEFs showed significantly lower nuclear Trp53 
and p21 than Spry2+/– MEFs (Figure 3D). The endogenous 
PTEN only associated with TP53 in SPRY2-deficient DU145 
and MEFs (Figure 4B and Supplemental Figure 4A). Also, only 
the nuclear expression of both WT and G129R PTEN increased 
TP53 and p21 levels in PTEN-deficient LNCaP cells (Figure 4C 
and Supplemental Figure 4B). SPRY2-deficient DU145 cells and 
MEFs with TP53 KD showed diminished G1 arrest with associ-
ated decrease in p21 and increase in proliferation (Figure 4D 
and Supplemental Figure 4, C and D). To confirm the role of 
TP53 in nuclear PTEN–mediated growth arrest, WT and G129R 
PTEN tagged with either NES or NLS were expressed in PTEN- 
and TP53-deficient PC-3 cells with SPRY2 KD and WT-TP53 
expression. Importantly, the induction of G1 arrest by nuclear 
PTEN (WT and G129R) was observed only in WT TP53 express-
ing PC-3 cells, confirming that, in a TP53-proficient context, the 
phosphatase function of PTEN is dispensable for its antitumor 
effects (Supplemental Figure 4E). The WT PTEN-NES induced 
cell death independent of SPRY2 expression in TP53-null PC-3 
cells (Supplemental Figure 4E).
The prostates from PB-Cre4:Spry2+/– showed increased nuclear 
TP53 and p21 staining when compared with PB-Cre4:Ptenfl/+Spry2+/– 
mice (Figure 4E and Supplemental Figure 4, F and G). Also, the 
prostates from PB-Cre4:Spry2+/– Trp53fl/+ showed increased Ki67 
staining when compared with PB-Cre4:Trp53fl/+ mice (Supplemen-
tal Figure 4H). Overall, SPRY2 deficiency induced growth arrest 
via nuclear PTEN-mediated induction of TP53 and p21 indepen-
dent of its phosphatase activity.
SPRY2 deficiency–induced ROS increases nuclear accumulation of 
PTEN. Consistent with a previous report (25), nuclear PTEN in 
DU145 cells was upregulated following H2O2 treatment (Sup-
plemental Figure 5A), suggesting a possible role of intracellular 
ROS in nuclear localization of PTEN. Hence, ROS levels were 
assayed in SPRY2-deficient DU145 and MEF cells. SPRY2 KD 
increased ROS levels in the presence of 10% serum supplement, 
an effect not observed in cells maintained in serum-free medium 
(Figure 5A). SPRY2 is a negative regulator of FGFR signaling, 
while PTEN’s phosphatase function is essential for negative 
feedback regulation of activated IGFR (15, 26). Consistent with 
this, IGF-1 and FGF-2 activated AKT and ERK more potently 
in SPRY2 KD DU145 cells, indicating increased RTK signal-
ing (Supplemental Figure 5B). SPRY2-deficient cells showed 
increased ROS production upon FGF-2 and IGF-1 treatment, 
which was abolished by treatment with specific inhibitors, 
namely BIBF1120 and PPP (inhibitors for FGFR and IGF-1R 
respectively; Figure 5B and Supplemental Figure 5C). Thus, 
SPRY2 loss increased intracellular ROS by enhancing RTK acti-
vation. RTK-mediated induction of intracellular ROS is report-
ed to involve activation of the NADPH oxidase enzyme complex 
(27). As expected, in SPRY2 KD cells, treatment with the NADPH 
oxidase inhibitor apocynin significantly reduced the ROS lev-
els and PTEN nuclear localization (Supplemental Figure 5D). 
Treatment with a ROS quencher DTT potently decreased nucle-
ar localization of PTEN, implicating a significant role of ROS in 
elevating nuclear PTEN levels in SPRY2 KD cells (Supplemental 
Figure 5E). Furthermore, treatment with the antioxidant N-ace-
tyl cysteine (NAC) decreased nuclear Pten and p21 staining in 
Spry2+/– MEFs (Figure 5C). Similarly, NAC treatment in SPRY2 
KD DU145 cells also abolished nuclear accumulation of PTEN, 
TP53, and p21 with associated decrease in G1 arrest (Figure 5D). 
In an orthotopic PC model, mice injected with DU145 (Nsi or 
SRPY2 KD CL61) cells were treated with NAC for 5 weeks to test 
its effects on tumor growth. Consistent with our in vitro find-
ings, NAC treatment increased the tumor incidence of SPRY2 
KD cells to 100% (7/7), compared with 42% (3/7) in vehicle con-
trol–treated mice, with a significant increase in tumor burden 
and proliferation (Figure 5, E and F, and Supplemental Figure 
5F). The tumor incidence, burden, and proliferation were unal-
tered by NAC treatment in mice injected with Nsi cells (Figure 5, 
E and F, and Supplemental Figure 5F). NAC treatment also 
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decreased nuclear PTEN, TP53, and p21 staining in SPRY2 KD 
orthotopic tumors (Figure 5F and Supplemental Figure 5F). To 
confirm that the growth-promoting effects of NAC are depen-
dent on PTEN in SPRY2-deficient cells, mice injected with con-
trol and SPRY2-expressing LNCaP (PTEN and SPRY2 deficient) 
cells were treated with NAC for 5 weeks. As expected, LNCaP 
cells with stable SPRY2 expression showed significantly lower 
tumor burden and proliferation (P < 0.01, respectively). NAC 
treatment in these mice did not alter the tumor incidence, bur-
den, or proliferation (Supplemental Figure 5, G and H). Also, 
NAC-induced increase in cell proliferation in SPRY2 KD DU145 
cells was abrogated upon PTEN KD (Supplemental Figure 5I). 
Overall, we show that SPRY2 loss–induced ROS drives nuclear 
PTEN–mediated growth arrest.
GSK3B activation drives phosphorylation and nuclear accumulation 
of PTEN. PB-Cre4:Spry2+/– mice treated with NAC also showed 
decreased nuclear Pten and p21, with significant increase in 
Ki67 staining in the prostatic tissues (Figure 6, A and B, and 
Supplemental Figure 6, A and B). Interestingly, NAC treat-
ment decreased PTEN phosphorylation in the prostates of 
PB-Cre4:Spry2+/– mice and SPRY2 KD DU145 cells (Figure 5, 
C and D). Similarly, induction of ROS by H2O2 treatment 
in DU145 cells increased and treatment of SPRY2 KD cells 
with DTT (ROS quencher) decreased PTEN phosphorylation 
(Supplemental Figure 6, C and D). To test the significance of 
PTEN phosphorylation on its nuclear localization, WT and 
phosphorylation-deficient PTEN-GFP (PTENS380F and PTEN 
T382/383A) mutants were expressed in SPRY2-null LNCaP cells. 
Both S380F and T382/383A PTEN mutants showed decreased 
nuclear accumulation when compared with WT PTEN (Sup-
plemental Figure 6E), suggesting a role for PTEN phosphory-
lation at Ser380/Threo382/Threo383 residues in its nuclear 
localization. Since PTEN is phosphorylated by GSK3B (28), 
GSK3B expression was knocked down in SPRY2 KD DU145 
cells. GSK3B KD potently decreased nuclear localization and 
phosphorylation of PTEN in SPRY2 KD cells with an associated 
increase in cell proliferation (Figure 6, E and F, and Supplemen-
tal Figure 6F). Treatment of SPRY2-deficient MEFs and DU145 
cells with specific GSK3B inhibitor (SB216763) significantly 
decreased PTEN phosphorylation (Figure 6G and Supplemen-
tal Figure 6G). To further confirm the role of GSK3B activity in 
DU145 cells, we generated SPRY2 KD and Nsi DU145 cells with 
stable expression of either kinase-defective (K85A) or constitu-
tively active (S9A) GSK3B. GSK3BK85A expression significantly 
decreased PTEN phosphorylation and nuclear localization in 
SPRY2 KD cells with associated decrease in G1 arrest (Figure 6H 
and Supplemental Figure 6, H and I). Conversely, GSK3BS9A 
expression significantly elevated PTEN phosphorylation and 
nuclear localization with associated increased in G1 arrest in Nsi 
control cells (Figure 6H and Supplemental Figure 6, H and I). 
Here, we show that GSK3B-mediated phosphorylation of PTEN 
at S380/T382/T383 governs its nuclear localization.
ROS-mediated PP2A activation increases phosphorylation and nuclear 
localization of PTEN via GSK3B. GSK3B activity is tightly regulat-
ed by the phosphorylation status at serine 9, which is induced by 
inactivating kinases such as AKT and reduced by activating phos-
phatases such as PP2A (29). Despite increased AKT activation in 
SPRY2-deficient cells (Figure 1, A–C), GSK3B showed decreased 
inactivating phosphorylation at serine 9 in SPRY2-deficient 
cells, indicating enhanced phosphatase function to activate 
GSK3B (Figure 6, C and D, and Supplemental Figure 6D). 
Therefore, the potential involvement of PP2A was investigated. 
PP2A activity was significantly elevated in SPRY2 KD DU145 
cells; this activity could be further enhanced by FTY720 (PP2A 
activator) or inhibited by okadaic acid (a selective PP2A inhibi-
tor), respectively (Figure 7A and Supplemental Figure 7A). Also, 
Spry2+/– MEFs and murine prostatic tissues showed increased 
PP2A activity (Figure 7A and Supplemental Figure 7B). The role 
of PP2A in GSK3B-mediated PTEN phosphorylation was tested 
using okadaic acid and knocking down structural (PP2A-A) or 
catalytic (PP2A-C) subunits of PP2A. All the treatments that 
diminished PP2A function enhanced inactivating phosphory-
lation of GSK3B, decreased p-PTEN, and diminished nuclear 
localization of PTEN in SPRY2 KD cells (Figure 7, B–D, Sup-
plemental Figure 7, C–F, and Supplemental Figure 8, H and I). 
Endogenous SPRY2 was able to bind to both A and C core sub-
units of PP2A in both DU145 and MEF cells (Supplemental 
Figure 8A). In SPRY2-deficient cells, GSK3B showed increased 
association with PP2A-A (Figure 7E). Moreover, in SPRY2 KD 
DU145 cells, GSK3B-associated PP2A activity was significantly 
increased; this increase could be further enhanced by FTY720 or 
inhibited by okadaic acid treatment (Figure 7F). Thus, in addi-
tion to regulating overall PP2A activity, SPRY2 loss may also 
alter PP2A substrate specificity.
While SPRY2 deficiency is associated with increased PP2A 
activity in DU145 cells, MEFs, and prostatic tissues, we observed 
that treatment with the antioxidant NAC abolished such PP2A 
activation (Figure 7A and Supplemental Figure 7B). Induction 
of ROS by H2O2 treatment significantly increased PP2A activity 
in DU145 cells (Supplemental Figure 7H). Similarly, decreas-
ing ROS levels by apocynin or DTT treatment abolished PP2A 
activation in SPRY2 KD cells (Supplemental Figure 7, I and J). 
Thus, ROS may regulate nuclear PTEN levels in DU145 SPRY2 
KD cells by sequential activation of PP2A and GSK3B. In SPRY2 
KD DU145 cells, both PP2A inhibitor (okadaic acid) and GSK3B 
Figure 5
SPRY2 deficiency–induced ROS increases nuclear accumulation of 
PTEN. (A) DU145 and MEFs were analyzed for intracellular ROS using 
DCFDA dye in the presence and absence of 10% serum (*P < 0.01; 
n = 3, analyzed by Mann-Whitney test). (B) Intracellular ROS was 
detected using DCFDA dye and analyzed in 24-hour serum-starved 
DU145 cells following treatment with growth factors (FGF2 [10 ng/ml], 
IGF-1 [100 ng/ml]) along with respective inhibitors (FGFR inhibitor- 
BIBF1120 [0.4 μM], IGF-1R inhibitor, PPP [2 nM]) for 30 minutes. SS, 
serum starved. (*P < 0.01; n = 3, analyzed by Mann-Whitney test). 
(C) Representative immunofluorescence images of MEFs stained for 
Pten (green) and p21 (red) after 5 μM NAC treatment for 48 hours. 
Scale bars: 100 μm. (D) Nuclear extracts from DU145 cells treated 
with 5 μM NAC for 48 hours were analyzed by Western blot, and G1 
cells were quantified (*P < 0.001; n = 3, analyzed by Mann-Whitney 
test). (E) Representative images and prostate weights of nude mice 
orthotopically injected with Nsi or SPRY2 KD (CL61) DU145 cells and 
treated with NAC. Scale bars: 0.5 cm. (*P < 0.01, number of mice = 7, 
analyzed by Dunnett’s multiple comparison test). Box and whisker 
plots show median (lines within boxes), interquartile range (bounds 
of boxes), and upper and lower range (whiskers). (F) Representative 
images of IHC for Ki67, PTEN, TP53, and p21 in indicated DU145 
orthotopic tumors. Scale bars: 100 μm. All the Western blots were 
quantified using ImageJ, and the values represent relative immunore-
activity of each protein normalized to respective loading control. Data 
are presented as mean ± SEM (A, B, and D).
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in SPRY2-deficient DU145 and MEFs (Figure 9D). In contrast, 
activation of PP2A by FTY720 enhanced G1 population in both 
control and SPRY2 KD cells (Figure 9D). Importantly, FTY720-
treated mice with s.c. xenografts of DU145 cells showed sig-
nificantly reduced tumor growth with increased PP2A activity 
when compared with vehicle-treated mice (Figure 9, E and F, and 
Supplemental Figure 8L). These xenografts also showed signifi-
cantly less Ki67 and enhanced nuclear PTEN and p21 staining 
(Figure 9G). Overall, we have identified a PP2A-induced check-
point in SPRY2-deficient cells. Mechanistically, PP2A-induced 
growth arrest depends on GSK3B, which is ultimately mediated 
by nuclear PTEN.
In murine PC model, Pten loss bypasses Spry2 deficiency–induced 
growth arrest to synergistically drive tumorigenesis. Our data sug-
gest that in the context of SPRY2 loss, regulation of PTEN 
status represents a key factor in controlling prostate carcino-
genesis. Confirming this, we find that the dual heterozygous 
PB-Cre4:Ptenfl/+Spry2+/– mice showed increased number of 
hyperplastic lesions and prostatic intraneoplasia (PIN) when 
compared with PB-Cre4:Ptenfl/+ mice at 6 months (Figure 10A 
and Supplemental Figure 9A). As previously reported, the 
prostates of PB-Cre4:Ptenfl/+ mice developed hyperplastic 
lesions with increased frequency of PIN at 1 year. In contrast, 
PB-Cre4:Ptenfl/+Spry2+/– mice developed invasive tumors at 1 year 
(Figure 10, A and B, and Supplemental Figure 9B). The pros-
tate tissue of PB-Cre4:Spry2+/– mice showed increased p21 stain-
ing despite enhanced Akt and Erk1/2 activation at both 6 and 
12 months (Figure 10C and Supplemental Figure 9, C–E). In 
contrast, the prostates of PB-Cre4:Ptenfl/+Spry2+/– mice showed 
decreased p21 staining (Figure 10C and Supplemental Figure 9, 
C–E) and the tumors from PB-Cre4:Ptenfl/+Spry2+/– mice showed 
increased Ki67 staining and Akt activation relative to prostatic 
tissue from PB-Cre4:Ptenfl/+ mice (Figure 10C and Supplemental 
Figure 9, E and F). The PIN lesions in PB-Cre4:Ptenfl/+Spry2+/– 
mice showed enhanced Erk activation, while PINs in 
PB-Cre4:Ptenfl/+ mice showed minimal Erk activation (Figure 10C 
and Supplemental Figure 9D). However, the majority of the 
prostate tumors from PB-Cre4:Ptenfl/+Spry2+/– mice at 12 months 
showed enhanced Akt activation with localized Erk activation 
(Figure 10C). Interestingly, PB-Cre4:Ptenfl/+Spry2+/– mice also 
showed enlarged lymph nodes, with evidence of metastasis as 
seen by pan-cytokeratin staining (Figure 10D). Consistent with 
probable epithelial-to-mesenchymal transition, prostate tumors 
from PB-Cre4:Ptenfl/+Spry2+/– mice showed delocalized (nonmem-
branous) E-cadherin and elevated vimentin staining (Supple-
mental Figure 9G). Similarly, in a mouse orthotopic prostate 
model using DU145 cells, NAC treatment, which enhanced over-
all tumor incidence of SPRY2 KD cells, also increased the inci-
dence of metastasis and distant organ (liver) metastasis (Supple-
mental Figure 9H and Supplemental Table 1). Thus, Spry2 and 
Pten inactivation synergistically drive murine PC progression.
Impact of SPRY2, PTEN, and PP2A status in clinical PC. We next 
tested the clinical relevance of SPRY2 loss and nuclear PTEN in 
PC. In a cohort of clinical PC (n = 244), SPRY2 staining was sig-
nificantly reduced in the malignant epithelium when compared 
with benign prostatic hyperplasia (BPH) (Figure 11A). Consistent 
with its role as a tumor suppressor, nuclear and cytosolic levels 
of PTEN in tumors were significantly lower in PC (Figure 11A). 
Confirming our in vitro and in vivo data, SPRY2 showed a sig-
nificant inverse correlation with nuclear PTEN and p21 staining 
inhibitor (SB216763) treatments decreased nuclear PTEN local-
ization and nuclear p-PTEN levels (Figure 8A and Supplemental 
Figure 7K). In contrast, activation of PP2A by FTY720 treatment 
enhanced total and phosphorylated levels of nuclear PTEN in 
both Nsi and SPRY2 KD cells (Figure 8A and Supplemental 
Figure 7K). Similarly, in Spry2+/– MEFs, inhibition of PP2A and 
Gsk3b decreased nuclear Pten and p21 staining, while FTY720 
treatment increased their staining in WT MEFs (Supplemental 
Figure 7M). Furthermore, FTY720-induced effects on PTEN 
required both PP2A and GSK3B, as FTY720-induced PTEN phos-
phorylation was eliminated by KD of either PP2A-A (Figure 8B 
and Supplemental Figure 7D) or GSK3B (Figure 8C and Supple-
mental Figure 7L). Overall, we show that SPRY2 loss–induced 
ROS drives nuclear accumulation of PTEN by PP2A-mediated 
activation of GSK3B.
PP2A activation suppresses tumorigenesis by increasing nuclear local-
ization of PTEN. Our work so far showed that PP2A activation 
may act as a check point to inhibit tumorigenesis by activating 
tumor suppressors GSK3B and PTEN. To further confirm this, 
we tested the effects of overexpressing the structural A subunit 
and the catalytic C subunit of the PP2A enzyme complex in 
DU145 cells, which express relatively low levels of PP2A sub-
units (Supplemental Figure 8A). As expected, restoring PP2A-A 
and PP2A-C expression to higher levels increased overall PP2A 
activity with an associated decrease in serine 9 phosphorylation 
of GSK3B and increase in p-PTEN levels (Supplemental Figure 
8, B–E). DU145 cells with PP2A-A overexpression also showed 
elevated nuclear staining of PTEN and increased G1 arrest (Sup-
plemental Figure 8, F and G). We next tested the role of GSK3B 
in PP2A-mediated effects on PTEN by knocking down GSK3B 
in PP2A-A–overexpressing DU145 cells. GSK3B KD abrogated 
PP2A–mediated increase in phosphorylation and nuclear local-
ization of PTEN and associated growth arrest without affect-
ing overall PP2A activity (Figure 9, A and B, and Supplemental 
Figure 8J). Also, Nsi and SPRY2 KD cells with stable expression 
of constitutively active GSK3B (S9A) showed elevated p-PTEN 
levels irrespective of PP2A status or activity (Figure 9C). Simi-
larly, in Nsi and SPRY2 KD cells with stable expression of 
kinase-deficient GSK3B (K85A), FTY720-mediated increase in 
PP2A activity failed to increase PTEN phosphorylation (Supple-
mental Figure 8K). Furthermore, suppression of PP2A function 
by okadaic acid treatment significantly decreased growth arrest 
Figure 6
GSK3B activation drives phosphorylation and nuclear accumula-
tion of PTEN. (A and B) Representative images of (A) PTEN (red) 
immunofluorescence and of (B) Ki67 and p21 IHC on prostate tissue 
from WT and Spry2+/– mice treated with 10 mM NAC for 75 days in 
drinking water ad libitum. Scale bars: 50 μm. (C) Western blot analysis 
of WCL from prostates of indicated mice treated with 10 mM NAC for 
75 days in drinking water ad libitum. (D) Western blot analysis of indi-
cated DU145 cells treated with 10 μM NAC for 12 hours. (E) Western 
blot analysis of DU145 cells treated with GSK3B siRNA. (F) Represen-
tative PTEN immunofluorescence images of DU145 cells treated with 
GSK3B siRNA. Scale bars: 50 μm. (G) Western blot analysis of indi-
cated MEFs treated with Gsk3b inhibitor SB216763 (5 μM for 12 hours). 
(H) Western blot analysis of DU145 SPRY2 KD clones with stable 
expression of kinase dead (GSK3BK85A) and constitutively active 
(GSK3BS9A) GSK3B. All the Western blots were quantified using 
ImageJ, and the values represent relative immunoreactivity of each 
protein normalized to respective loading control.
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In this data set, 20% of the cases showed significant (more than 
2-fold) decrease in SPRY2, and, among these tumors, approxi-
mately 90% showed associated loss of either PTEN or PP2A sub-
units (Supplemental Figure 10C). Furthermore, 38% of meta-
static prostate tumors showed loss of SPRY2 expression and the 
majority of these tumors showed concomitant decrease in either 
PTEN or PPP2CB (PP2A-C) expression (Figure 11D). These data 
suggest that loss of either PTEN or PP2A is necessary and suffi-
cient to synergistically cooperate with SPRY2 deficiency to drive 
PC (Figure 11E).
Discussion
The recent report by Ding et al. has highlighted the complex 
nature of disruptive events during PC progression and sug-
gested the need to understand the genesis of PC in the context 
of events such as PTEN inactivation (31). Our work has iden-
tified SPRY2 loss and PP2A inactivation as additional lesions 
that cooperate with PTEN in PC progression (Figure 11E). This 
provides insights into how interactions among major tumor 
suppressors influencing key signaling pathways may facilitate 
the development of therapeutic strategy and biomarkers. Con-
current mutations in components of the PTEN/PI3K/AKT and 
SPRY2/RAS/ERK pathways leading to simultaneous activation 
of these oncogenic cascades have been described in a number of 
cancer types, including colon, endometrium. and pancreas (32). 
in BPH (Figure 11B and Supplemental Table 2). Interestingly, 
in BPH, nuclear PTEN showed a significant correlation with 
p-AKT levels, suggesting that nuclear localization of PTEN may 
increase PI3K-AKT activation (Figure 11B and Supplemental 
Table 2). We also confirmed a strong correlation between SPRY2 
and PTEN in our tumor cohort (Table 1). As previously shown, 
PTEN showed significant inverse correlation to p-AKT, whereas 
there was no evidence of association with p-ERK (Table 1). As 
seen in our in vivo models, SPRY2 expression showed a signifi-
cant inverse correlation with both p-AKT and p-ERK, which 
were strongly associated mutually, underscoring the nature 
of dual pathway activation (Table 1). Among patients bearing 
tumors with low SPRY2 levels, cases with nuclear PTEN-posi-
tive tumors have a significantly better survival outcome than 
those with tumors negative for nuclear PTEN, supporting our 
model that, by enhancing nuclear PTEN, SPRY2 loss in isolation 
has a tumor-suppressing, rather than tumor-promoting effect 
(Figure 11C). Overall, the expression status of PTEN and SPRY2 
did not significantly influence patient survival as individual fac-
tors (Supplemental Figure 10A). Expression analysis of SPRY2 
in a clinical PC data set from cBio Cancer Genomics Portal (2, 
30) showed overall decrease in expression in tumors (Supple-
mental Figure 10B). In the same data set of primary prostate 
tumors SPRY2 expression strongly correlated with both PTEN 
(ρ = 0.367; P < 0.01) and PPP2CB (PP2A-C) (ρ = 0.423; P < 0.01). 
Figure 7
ROS-mediated PP2A activation increases phosphorylation of PTEN. (A) PP2A activity was measured in DU145 and MEFs (*P < 0.05, analyzed 
by Mann-Whitney test), and PP2A-C IP was analyzed by Western blot. (B–D) Western blot analysis of indicated DU145 cells treated with (B) 
1 μM okadaic acid for 2 hours, (C) 5 nmol PP2A-A siRNA for 42 hours, and (D) 5 nmol PP2A-C siRNA for 42 hours. (E) PP2A-A IP from DU145 
and MEFs was analyzed by Western blot. (F) PP2A activity and Western blot of GSK3B IP in DU145 cells treated with 1 μM okadaic acid and 
10 μM FTY720 for 2 hours (*P < 0.05, n = 3, analyzed by Mann-Whitney test). All Western blots were quantified using ImageJ, and the values 
represent relative immunoreactivity of each protein normalized to respective loading control. Data are presented as mean ± SEM (A and F).
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TP53 that functions to provide a primary fail-safe response of 
growth arrest to PI3K/AKT and RAS/ERK activation by onco-
genic stimulus of SPRY2 loss.
Using a range of in vitro models as well as in vivo murine 
and clinical prostate tissues, we show that loss of SPRY2 regu-
lates PTEN localization to induce growth arrest despite para-
doxical and simultaneous activation of AKT and ERK. Since 
Molecular analyses have shown that concomitant activation of 
both PI3K/AKT and RAS/ERK pathways synergize to bypass the 
primary tumor-suppressive responses such as senescence (3). 
In this study, we present evidence to suggest that, surprisingly, 
mere activation of oncogenic signaling cascades is insufficient 
to drive tumorigenesis. We have identified a network of impor-
tant tumor suppressors involving PTEN, PP2A, GSK3B, and 
Figure 8
PP2A activation drives PTEN phosphorylation and nuclear localization via GSK3B. (A) Representative immunofluorescence images of oka-
daic acid–treated (0.5 μM for 1 hour), FTY720-treated (10 μM for 6 hours) and SB216763-treated (5 μM for 12 hours) DU145 cells stained 
for PTEN (green). Scale bars: 50 μm. (B) Western blot analysis of DU145 cells treated with 5 nmol PP2A-A siRNA for 24 hours followed by 
5 μM FTY720 for 12 hours as indicated. (C) Western blot analysis of DU145 cells treated with GSK3B siRNA for 24 hours followed by 5 μM 
FTY720 for 12 hours. All Western blots were quantified using ImageJ, and the values represent relative immunoreactivity of each protein 
normalized to respective loading control.
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in prostate carcinogenesis (37). The role of antioxidants as che-
mopreventive agents in clinical trial has been disappointing, with 
data from the discontinued SELECT PC prevention trial suggest-
ing an unexpected trend (P = 0.06) toward increased risk, rather 
than protection from, clinical PC in men taking the antioxidant 
vitamin E (38). Based on our findings, the use of antioxidants can 
potentially promote tumor progression in the context of reduced 
SPRY2 expression. Hence, we propose that future trials should 
incorporate expression status of SPRY2 and PTEN for patient 
stratification in their design. Alternatively, the fallback tumor-
suppressive pathways such as PP2A activation as identified here 
can be exploited for cancer prevention.
Mechanistically, we show that SPRY2 loss–mediated increase 
in ROS induced nuclear accumulation of PTEN via PP2A activa-
tion. Posttranslational modifications (PMTs) of PTEN such as 
ubiquitylation and phosphorylation have been previously impli-
cated in cellular distribution of PTEN (14, 25). Here, we show 
that phosphorylation of PTEN at Ser380/Threo382/Threo383 
can promote nuclear accumulation of PTEN. Consistent with a 
previous report, we show GSK3B as an important mediator of 
PTEN phosphorylation (27). The counterintuitive activation of 
GSK3B despite AKT activation was mediated by PP2A activa-
tion. SPRY2 KD induced intracellular ROS-mediated sequential 
activation of PP2A and GSK3B to increase PTEN phosphoryla-
tion and nuclear accumulation. Interestingly, we also observed 
increased binding of the core PP2A subunit PP2A-A to GSK3B 
in SPRY2-deficient cells, suggesting an altered PP2A substrate 
specificity in the absence of SPRY2. Since our data and previ-
ous reports indicate association of SPRY2 with core PP2A sub-
units, we hypothesize that loss of SPRY2 may change substrate 
specificity of PP2A to deregulate various signaling cascades 
(20). The core structural (PP2A-A) and catalytic (PP2A-C) sub-
units of PP2A are essential for its tumor-suppressive activity. 
The MSKCC clinical PC data set shows decreased expression of 
PP2A-A in almost 19% of primary prostate tumors (30). Con-
sistent with the haploinsufficient tumor-suppressive functions 
of PP2A-A, we observed lower levels of PP2A-A in DU145 and 
PC-3 PC cells relative to RWPE-1 normal prostate cells. Hence, 
by restoring the PP2A-A levels in DU145 cells, we observed 
enhanced PP2A activity as well as tumor-suppressive effects. 
Most importantly, for what we believe is the first time, our data 
indicate that PP2A may play an important tumor-suppressive 
role by enhancing nuclear accumulation of PTEN. Hence, acti-
vation of PP2A can be considered a novel strategy to prevent 
prostate carcinogenesis.
Nuclear PTEN has been implicated in maintaining stem cell 
quiescence (39, 40). Interestingly, prostatic epithelial cells in 
Spry2+/– mice showed an increased tendency for nuclear Pten 
localization and decreased proliferation. This is consistent 
with our clinical survival data indicating a significantly bet-
ter outcome for patients with tumors showing reduced SPRY2 
expression in the presence of nuclear PTEN (P = 0.001). In con-
trast, the prostatic epithelium of PB-Cre4:Ptenfl/+Spry2+/– mice 
showed enhanced proliferation, suggesting that simultane-
ous loss of Spry2 and Pten may synergize to promote PC. Sup-
porting this hypothesis, we find that Spry2 heterozygosity in 
PB-Cre4:Ptenfl/+Spry2+/– mice promotes PC from precancerous 
lesions as observed in PB-Cre4:Ptenfl/+ mice to invasive tumors. 
Spry2 deficiency also increased metastasis in murine PC mod-
els, which is supported by the global genomic analysis by Taylor 
phosphorylated PTEN is unable to associate with plasma mem-
brane and inhibit PI3K signaling, phosphorylation of PTEN can 
act as an important oncogenic stimulus (8). Here we show that 
the activation of PI3K signaling upon SPRY2 loss is at least in 
part mediated by PTEN phosphorylation. SPRY2 has been pre-
viously shown to inhibit cell proliferation by enhancing PTEN 
activity (23). In contrast with this report, despite increased AKT 
activity, SPRY2 KD PTEN-proficient PC cells proliferate more 
slowly and undergo G1 arrest. Beyond its cytoplasmic role in 
inhibition of the PI3K pathway, it is now clear that when local-
ized to the nucleus, PTEN can suppress tumor progression by 
inducing growth arrest (10, 33). For the first time, loss of SPRY2 
has been shown to induce G1 arrest via nuclear accumulation 
of PTEN. In agreement with previous reports, nuclear PTEN, 
independent of its lipid phosphatase activity, physically inter-
acts and stabilizes TP53 to induce G1 arrest (34). This suggests 
that in addition to the previously reported role of SPRY2 in 
inhibition of cell proliferation by PTEN activation and subse-
quent inhibition of the PI3K pathway, SPRY2 inactivation can 
also trigger tumor-suppressive effects of PTEN by enhancing its 
nuclear accumulation. Supporting this, Chang et al. have shown 
that, independent of its phosphatase activity, nuclear expression 
of PTEN in PC cells such as LNCaP can inhibit tumorigenesis 
(25). Also, the phosphatase mutant PtenC124R/+ heterozygous 
mice showed fewer proliferative lesions in the prostate when 
compared with Pten+/– mice, underscoring the phosphatase-
independent functions of Pten (35).
Deregulated RTK signaling can enhance intracellular ROS as 
an intrinsic part of their signaling cascade (36). Consistent with 
this and considering the role of SPRY2 as a negative regulator of 
RTK signaling, we show that the observed increase in ROS upon 
SPRY2 loss is mediated by enhanced RTK signaling. We have also 
identified SPRY2 loss–induced oxidative stress as a key regula-
tor of nuclear localization of PTEN and tumor suppression. Of 
note, antioxidants have been proposed as chemopreventive agents 
Figure 9
PP2A activation suppresses tumorigenesis by increasing nuclear local-
ization of PTEN. (A) DU145 cells infected with control and PP2A-A– 
expressing viruses were treated with GSK3B siRNA for 24 hours and 
analyzed by Western blot and WST-1 assay for measuring cell pro-
liferation (*P < 0.01; n = 3). (B) Representative immunofluorescence 
images of PP2A-A–expressing DU145 cells treated with GSK3B 
siRNA for 24 hours and stained for PTEN. Scale bars: 50 μm. (C) 
Western blot analysis of DU145 SPRY2 KD clones with stable 
expression of constitutively active GSK3B (S9A) treated with 5 nmol 
PP2A-A siRNA for 42 hours. (D) DU145 and MEF cells treated with 
0.2 μM okadaic acid or 10 μM FTY720 for 12 hours were quanti-
fied for percentage of G1 cells (*P < 0.01; n = 3). (E) Representative 
images and PP2A activity measurement in s.c. xenografts of DU145 
cells in nude mice treated with PP2A activator FTY720 (10 mg/kg/d 
i.p. injection) for 5 days. (*P < 0.01; n = 5). (F) Representative images 
and tumor burden of s.c. injected DU145 cells in nude mice treated as 
indicated. Red line indicates schedule of FTY720 treatment (10 mg/kg/d 
i.p. injection). (G) Representative IHC images and quantification of 
Ki67 (white), PTEN (gray), and p21 (blue) in DU145 s.c. xenografts 
treated as above. Scale bars: 50 μm. Box and whisker plots (E and G) 
show median (lines within boxes), interquartile range (bounds of 
boxes), and upper and lower range (whiskers). The values of Western 
blot represent relative immunoreactivity of each protein normalized to 
respective loading control. Data are presented as mean ± SEM and 
analyzed by Mann-Whitney test (A and D–F).
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model, dorsolateral prostates of male CD-1 nude mice were injected with 
3 × 106 cells/25 μl serum free RPMI as previously described (42). The mice 
were gavaged daily for 5 weeks with NAC (10 mM) as indicated. WT and 
Spry2+/– mice were treated with 10 mM NAC (pH 7.5) in drinking water ad 
libitum for 75 days, and the NAC water was changed twice weekly. For the 
xenograft model, 107 DU145 cells were injected in 100 μl of serum-free 
medium s.c. in CD-1 nude mice. During the second week after injections, 
mice were randomized and treated with vehicle or FTY720 until the end of 
fifth week. The tumor volume was measured weekly using venire calliper. 
For the orthotopic tumor model, NAC and vehicle treatments were initi-
ated 3 weeks after orthotopic injections. After a period of 8 weeks, mice 
were scarified after BrdU injection. S.c. and prostate tumors were excised, 
weighted, and fixed in formalin for 24 hours. Mice were sacrificed at time 
points of 3 months for proliferation studies, with a further cohort aged 
to 6 and 12 months for tumorigenic studies. The excised prostates were 
placed in formalin for overnight fixation before paraffin embedding.
Plasmids and siRNA. A 19-mer SPRY2 target sequence (5′-AACACCAAT-
GAGTACACAGAG-3′) from the 5′ end of the SPRY2 cDNA previously 
identified employing RNAi on-line tools (QIAGEN) and validated in suc-
cessful siRNA KD experiments was inserted as a hairpin sequence into 
pTER+ plasmid (ShSPRY2). Alternatively, a 19-mer Nsi control sequence 
from QIAGEN was also inserted into the pTER+ as a Nsi shRNA control 
(shNsi). The shRNA vector pTER+ was made by inserting a modified H1 
promoter cassette between the BglII and HindII sites of pcDNA4/TO 
(Invitrogen) as previously described (43). Cells stably expressing shSPRY2 
and shNsi were selected using zeocin (300 μg/ml; Invitrogen). SPRY2 
expression construct used for stable and transient expression was a gift 
from Graeme Guy (Institute of Molecular and Cell Biology, Singapore). 
Cells stably expressing SPRY2 were selected using geneticin (500 μg/ml; 
Gibco, Invitrogen). The PTEN siRNA (6251) and p53 siRNA (6562) were 
obtained from Cell Signaling. The PTEN expression construct (EGFP-
PTEN) was generated by cloning PTEN cDNA (OriGene) into EcoRI/SalI-
cut EGFPC2 (Clontech) vector. The PTEN expression constructs pSG5L 
HA NLS PTEN (Addgene 864), pSG5L HA NES PTEN (Addgene 863), 
pSG5L HA NES PTENG129R (Addgene 867) and pSG5L HA NLS 
PTENG129R (Addgene 868) were obtained from Addgene (William Sell-
ers, Dana Farber Cancer Institute, Boston, Massachusetts, USA). Phos-
phorylation mutant (S380F and T382/383A) PTEN plasmids were gen-
erated from EGFP-PTEN plasmid using a site-directed mutagenesis kit 
(Alligent) and primers 5′-CCTGATCATTATAGATATTTTGACACCACT-
GACTCTGATCC-3′ (for S380F), 5′-CCTGATCATTATAGATATTCTGAC-
GCCACTGACTCTGATCC -3′ (for T382A), and 5′-CCTGATCATTATA-
GATATTCTGACGCCGCTGACTCTGATCC-3′ (for T382/383A using 
PTENT382A plasmid as the target). GSK3B expression constructs HA 
GSK3 β S9A pcDNA3 (14754) and HA GSK3 β K85A pcDNA3 (14755) 
were obtained from Addgene (Jim Woodgett, Samuel Lunenfeld Research 
Institute, Toronto, Ontario, Canada). Retroviral PP2A-A expression con-
struct pMIG-Aα WT (10884), empty backbone pMIG (9044), and PP2A-
C expression construct pBABE PPP2CA WT (10689) were obtained from 
Addgene (William Hahn, Dana Farber Cancer Institute).
Flow cytometry analysis. A total of 105 cells were acquired using a flow 
cytometer (FACScan, BD) and analyzed using Cell Quest Pro software.
PP2A activity assay. PP2A activity was measured using PP2A 
immunoprecipitation phosphatase assay kit by Millipore (#17-313) 
according to the manufacturer’s protocol. PP2A activity in cells with either 
PP2A-C KD or overexpression was measured using assay components from 
the kit and PP2A-A antibody by Millipore (# 07-250).
Human tissue microarray. Formalin-fixed, paraffin-embedded (FFPE) sec-
tions from 244 patients were studied. Tissue microarray (TMA) consisting 
of 209 primary PCs and 35 BPH samples was generated and used for IHC.
et al., showing reduced SPRY2 expression in 74% of metastatic 
tumors, significantly more prevalent than in primary tumors 
(18%) (2). Our in vivo data indicate that haploinsufficiency of 
Spry2 and Pten leads to invasive prostate tumors with associated 
Akt and localized ERK activation.
The clinical PC data sets show a decrease in overall expression 
of all 3 tumor suppressors, SPRY2, PTEN, and PP2A (PPP2CB). 
Supporting our in vitro and in vivo data, the expression analysis 
in clinical PC data sets showed significant correlation of SPRY2 
with PTEN and PP2A (P < 0.001). Furthermore, altered SPRY2, 
PTEN, and PPP2CB expression was associated with aggressive PC 
and decreased disease-free survival. We also observed an inverse 
correlation between SPRY2 and nuclear PTEN levels in BPH sam-
ples. In primary PC, almost all cases with SPRY2 loss show either 
loss of expression PTEN or PP2A subunits. Thus, it is plausible 
that loss of SPRY2 may represent an early event in prostate carci-
nogenesis whereby the presence of nuclear PTEN inhibits further 
progression. Such a state of “growth arrest” may be overcome by 
subsequent inactivation of PTEN, TP53, or PP2A.
In summary, our work has identified an intricate tumor-sup-
pressive network of SPRY2, PTEN, and PP2A in prostate carci-
nogenesis. We show what we believe to be a novel role of SPRY2 
in regulating cell fate by modulating PTEN function and its cel-
lular distribution besides its documented role in suppressing 
the PI3K and RAS pathways. PC with depleted SPRY2 levels may 
progress due to subsequent loss of PTEN or PP2A. We propose 
that the status of the SPRY2, PTEN, and PP2A trio may serve as 
a predictor of PC progression.
Methods
Cell lines and MEFs. Human PC cell lines DU145, PC-3, LNCaP, and 
CWR-22 were authenticated by LGC standards. For MEFs, the stable 
recombinations for PTEN were achieved by infecting MEFs with pBABE 
puro and pBABE puro-CRE (gift from Kevin Ryan, The Beatson Institute 
for Cancer Research) expressing adenoviruses and selecting the stable 
clones with 3 μg/ml puromycin (Sigma-Aldrich). The appropriate geno-
types selected for this study were checked by genotyping (Transnetyx 
Inc.) and Western blotting. Cell proliferation assays were carried out 
using WST-1 reagent (Roche).
Animal studies. For genetically modified mice, ARR2Probasin-Cre (PB-Cre4) 
mice with the Cre recombinase under the control of a modified rat proba-
sin promoter that is expressed in prostatic epithelium were crossed with 
Ptenfl/+ mice (41). These were further crossed with Spry2+/– mice obtained 
from Gail Martin (UCLA, Los Angeles, California, USA). For controls, WT 
littermates were used. For the xenograft model, 107 DU145 cells were inject-
ed in 100 μl of serum-free RPMI s.c. in CD-1 nude mice. For the orthotopic 
Figure 10
Spry2 and Pten inactivation synergistically drive murine prostate car-
cinogenesis. (A) Representative H&E-stained images of alterations in 
prostates from mice as indicated (n = 6). Scale bars: 50 μm. (B) Repre-
sentative prostate image and relative prostate weight of indicated mice 
at 12 months (*P < 0.01, n = 6, analyzed by Mann-Whitney Test). SV, 
seminal vesicles; AP, anterior prostate, DLP, dorsolateral prostate; B, 
bladder. Box and whisker plot shows median (lines within boxes), inter-
quartile range (bounds of boxes), and upper and lower range (whis-
kers). (C) Representative IHC images of prostate tissue from 12-month-
old mice as indicated (n = 6). Scale bars: 50 μm. (D) Representative 
IHC images for pancytokeratin staining in lymph nodes from indicated 
mice (n = 5). Scale bars: 50 μm.
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Figure 11
Impact of SPRY2, PTEN, and PP2A status in clinical PC. (A) TMA of clinical PC and BPH cohorts was analyzed for expression of SPRY2 and 
nuclear and cytoplasmic PTEN. Box and whisker plots show median (lines within boxes), interquartile range (bounds of boxes), and upper and 
lower range (whiskers). Data were analyzed by ANOVA using Dunnett’s multiple comparison test. (B) Representative IHC images in clinical BPH 
samples. Scale bars: 100 μm. (C) Kaplan-Meier survival plot for PC patients with reduced SPRY2 expression (below median histoscore); analysis 
was according to the levels of nuclear PTEN. (D) Heat map of alterations in SPRY2, PTEN, and PPP2CB (PP2A catalytic subunit) generated from 
metastatic tumors (27 cases) using MSKCC Prostate Oncogenome Project data set from cBio genomic portal. (E) Schematic of PC progression. 
SPRY2 loss leads to tumor suppression by inducing growth arrest via PP2A-mediated nuclear accumulation of PTEN. Subsequent inactivation 
of PTEN or PP2A as observed in clinical PC may drive tumor progression.
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All the human samples for TMA were taken from PC patients at the time 
of transurethral resection of the prostate, and their use in this study was 
approved by the Multicentre Research Ethics Committee for Scotland 
(MREC/01/0/36) (Edinburgh, United Kingdom). These archival clinical 
samples were “surplus to diagnostic need,” and specific consent from indi-
vidual patients was not deemed required by the Ethics Committee.
Detailed information is supplied in Supplemental Methods. The uncut 
gels for the respective figures are also included.
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Table 1
Prostate tumor histoscores from TMA were analyzed by Spear-
man’s rank order correlation using SigmaPlot 11.0 software
Spearman’s rank  PTEN  p-ERK  p-AKT  
order correlation (cytosolic) (cytosolic) (cytosolic)
SPRY2 0.434 –0.120 –0.199
 P < 0.0001 P = 0.05 P = 0.0001
p-AKT –0.171 0.401 
 P = 0.0109 P < 0.0001 
p-ERK –0.023  
 P = 0.754  
n = 209.
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